Abstract:You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology III1 Apr 2018MP88-15 HIGH ACTIVATION BUT NOT OVEREXPRESSION OF CAMP RESPONSIVE ELEMENT BINDING PROTEIN 1 (CREB1) IS AN FEATURE OF POOR PROGNOSIS IN ADVANCED CLEAR CELL RENAL CARCINOMA Liqun Zhou, Xuesong Li, and Yifan Li Liqun ZhouLiqun Zhou More articles by this author , Xuesong LiXuesong Li More articles by this author , and Yifan LiYifan Li More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2935AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Clear cell renal cell carcinoma (ccRCC) is clinically silent at their earliest stages, therefore, at the time of the initial diagnosis, up to 30% of patients have already progressed to a locally advanced disease state or exhibit metastases. cAMP responsive element binding protein 1 (CREB1) is a proto-oncogene in various cancer. This study was to explore the function and clinical significance of phosphorylated cAMP responsive element binding protein 1 (p-CREB1) at Ser 133 site in advanced ccRCC. The CREB1 phosphorylate pathway may be a novel target for kidney therapy. METHODS The expression of p-CREB1 (Ser133) and non p-CREB1 (Ser133) is determined by immunohistochemistry (IHC) in 151 advanved ccRCC patients. Through constructing lentiviral vector and using small molecular inhibitor, 666-15, the phosphorylated CREB (Ser133) are knockdown, overexpressed and inhibited. The proliferation of 786-0 cells in vitro and in vivo was determined by clone formation assay, MTS assay, and subcutaneous tumor formation in nude mice. To investigate the mechanisms, the interacting proteins of CREB1 were precipitated by pull-down assay and identified by mass spectrum. Then the proteins interaction was confirmed by co-immunoprecipitation in kidney cancer cells. Protein and mRNA expression level were measured by western blot and qPCR, respectively. RESULTS P-CREB1 (Ser133) and non p-CREB1 (Ser133) is highly expressed in ccRCC tissues. In multi-factor regression analysis, p-CREB1 (Ser133) is an independent risk factor but not non p-CREB1. The clone formation and proliferation ability is inbibted by phosphorylated CREB1 (Ser133) knockdown and 666-15, however, reversed by CREB1 (Ser133) overexpression. And subcutaneous tumor in nude mice is significantly shrinked by treating with 666-15.The interaction of CREB1 with serine/threonine-protein kinase 1 (SRPK1) and casein kinase II subunit beta (CSNK2B) were identified and confirmed in kidney cancer cells. The expression of p-CREB1 (Ser133) protein was higher in SRPK1 and CSNK2B overexpressed cells.Knockdown SRPK1 and CSNK2B, the p-CREB1 (Ser133) protein was decreased, the proliferation and migration ability were attenuated, and the cell apoptosis was induced in kidney cancer cells. CONCLUSIONS Highly expressed p-CREB (Ser133) is an independent risk of ccRCC patient. CREB1 was activated by SRPK1 and CSNK2 through phosphorylation. Target CREB1 phosphorylate pathway may inhibit the cancer phenotype of ccRCC. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1203 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Liqun Zhou More articles by this author Xuesong Li More articles by this author Yifan Li More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...